610 related articles for article (PubMed ID: 24504125)
1. Detection of cancer DNA in plasma of patients with early-stage breast cancer.
Beaver JA; Jelovac D; Balukrishna S; Cochran R; Croessmann S; Zabransky DJ; Wong HY; Toro PV; Cidado J; Blair BG; Chu D; Burns T; Higgins MJ; Stearns V; Jacobs L; Habibi M; Lange J; Hurley PJ; Lauring J; VanDenBerg D; Kessler J; Jeter S; Samuels ML; Maar D; Cope L; Cimino-Mathews A; Argani P; Wolff AC; Park BH
Clin Cancer Res; 2014 May; 20(10):2643-2650. PubMed ID: 24504125
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA.
Kim ST; Lira M; Deng S; Lee S; Park YS; Lim HY; Kang WK; Mao M; Heo JS; Kwon W; Jang KT; Lee J; Park JO
Oncotarget; 2015 Nov; 6(37):40026-35. PubMed ID: 26498688
[TBL] [Abstract][Full Text] [Related]
3. Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR
Moynahan ME; Chen D; He W; Sung P; Samoila A; You D; Bhatt T; Patel P; Ringeisen F; Hortobagyi GN; Baselga J; Chandarlapaty S
Br J Cancer; 2017 Mar; 116(6):726-730. PubMed ID: 28183140
[TBL] [Abstract][Full Text] [Related]
4. A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers.
Jelovac D; Beaver JA; Balukrishna S; Wong HY; Toro PV; Cimino-Mathews A; Argani P; Stearns V; Jacobs L; VanDenBerg D; Kessler J; Jeter S; Park BH; Wolff AC
Hum Pathol; 2014 Apr; 45(4):880-3. PubMed ID: 24444464
[TBL] [Abstract][Full Text] [Related]
5. PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients.
Oshiro C; Kagara N; Naoi Y; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2015 Apr; 150(2):299-307. PubMed ID: 25736040
[TBL] [Abstract][Full Text] [Related]
6. Detection of PIK3CA gene mutations with HRM analysis and association with IGFBP-5 expression levels in breast cancer.
Dirican E; Kaya Z; Gullu G; Peker I; Ozmen T; Gulluoglu BM; Kaya H; Ozer A; Akkiprik M
Asian Pac J Cancer Prev; 2014; 15(21):9327-33. PubMed ID: 25422220
[TBL] [Abstract][Full Text] [Related]
7. ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.
Chu D; Paoletti C; Gersch C; VanDenBerg DA; Zabransky DJ; Cochran RL; Wong HY; Toro PV; Cidado J; Croessmann S; Erlanger B; Cravero K; Kyker-Snowman K; Button B; Parsons HA; Dalton WB; Gillani R; Medford A; Aung K; Tokudome N; Chinnaiyan AM; Schott A; Robinson D; Jacks KS; Lauring J; Hurley PJ; Hayes DF; Rae JM; Park BH
Clin Cancer Res; 2016 Feb; 22(4):993-9. PubMed ID: 26261103
[TBL] [Abstract][Full Text] [Related]
8. Novel method for PIK3CA mutation analysis: locked nucleic acid--PCR sequencing.
Ang D; O'Gara R; Schilling A; Beadling C; Warrick A; Troxell ML; Corless CL
J Mol Diagn; 2013 May; 15(3):312-8. PubMed ID: 23541593
[TBL] [Abstract][Full Text] [Related]
9. PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer.
Markou A; Farkona S; Schiza C; Efstathiou T; Kounelis S; Malamos N; Georgoulias V; Lianidou E
Clin Cancer Res; 2014 Nov; 20(22):5823-34. PubMed ID: 25398847
[TBL] [Abstract][Full Text] [Related]
10. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
[TBL] [Abstract][Full Text] [Related]
11. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
[TBL] [Abstract][Full Text] [Related]
12. PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system.
Shimoi T; Hamada A; Yamagishi M; Hirai M; Yoshida M; Nishikawa T; Sudo K; Shimomura A; Noguchi E; Yunokawa M; Yonemori K; Shimizu C; Kinoshita T; Fukuda T; Fujiwara Y; Tamura K
Cancer Sci; 2018 Aug; 109(8):2558-2566. PubMed ID: 29906308
[TBL] [Abstract][Full Text] [Related]
13. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
Tzanikou E; Markou A; Politaki E; Koutsopoulos A; Psyrri A; Mavroudis D; Georgoulias V; Lianidou E
Mol Oncol; 2019 Dec; 13(12):2515-2530. PubMed ID: 31254443
[TBL] [Abstract][Full Text] [Related]
14. A Comparison Between Full-COLD PCR/HRM and PCR Sequencing for Detection of Mutations in Exon 9 of PIK3CA in Breast Cancer Patients.
Ghalamkari S; Khosravian F; Mianesaz H; Kazemi M; Behjati M; Hakimian SM; Salehi M
Appl Biochem Biotechnol; 2019 Mar; 187(3):975-983. PubMed ID: 30109561
[TBL] [Abstract][Full Text] [Related]
15. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood.
Higgins MJ; Jelovac D; Barnathan E; Blair B; Slater S; Powers P; Zorzi J; Jeter SC; Oliver GR; Fetting J; Emens L; Riley C; Stearns V; Diehl F; Angenendt P; Huang P; Cope L; Argani P; Murphy KM; Bachman KE; Greshock J; Wolff AC; Park BH
Clin Cancer Res; 2012 Jun; 18(12):3462-9. PubMed ID: 22421194
[TBL] [Abstract][Full Text] [Related]
16. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
17. EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR.
Buder A; Setinek U; Hochmair MJ; Schwab S; Kirchbacher K; Keck A; Burghuber OC; Pirker R; Filipits M
Target Oncol; 2019 Apr; 14(2):197-203. PubMed ID: 30810887
[TBL] [Abstract][Full Text] [Related]
18. Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H
Cancer Sci; 2015 Nov; 106(11):1582-9. PubMed ID: 26353837
[TBL] [Abstract][Full Text] [Related]
19. Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.
Qiu W; Tong GX; Manolidis S; Close LG; Assaad AM; Su GH
Int J Cancer; 2008 Mar; 122(5):1189-94. PubMed ID: 17990317
[TBL] [Abstract][Full Text] [Related]
20. Single-Nucleotide Polymorphism Leading to False Allelic Fraction by Droplet Digital PCR.
Christenson ES; Dalton WB; Chu D; Waters I; Cravero K; Zabransky DJ; DeZern AE; Park BH
Clin Chem; 2017 Aug; 63(8):1370-1376. PubMed ID: 28615231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
